To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Solvay

Status and phase: Completed; Phase 2

Conditions: Schizophrenia; Schizoaffective Disorder

Treatments: Drug: Bifeprunox

Study type: Interventional

Funder types: Industry

Identifiers

NCT00141479

S154.2.013

Details and patient eligibility

About

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Schizophrenia or Schizoaffective disorder
• 18-55 years

Exclusion criteria

• Subjects who are acutely psychotic
• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
• Subjects at significant risk of suicide
• Subjects with a seizure disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind